Accessibility Menu
Sutro Biopharma logo

Sutro Biopharma

(NASDAQ) STRO

Current Price$30.06
Market Cap$497.61M
Since IPO (2018)-81%
5 Year-85%
1 Year+265%
1 Month+17%

Sutro Biopharma Financials at a Glance

Market Cap

$497.61M

Revenue (TTM)

$99.61M

Net Income (TTM)

-$153.60M

EPS (TTM)

-$16.45

P/E Ratio

-1.83

Dividend

$0.00

Beta (Volatility)

1.32 (Average)

Price

$30.06

Volume

2

Open

$29.29

Previous Close

$30.03

Daily Range

$29.29 - $31.79

52-Week Range

$6.74 - $43.85

Estimated Earnings Date

Aug 6, 2026

STRO: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sutro Biopharma

Industry

Biotechnology

Employees

137

CEO

Jane Chung

Headquarters

South San Francisco, CA 94080, US

STRO Financials

Key Financial Metrics (TTM)

Gross Margin

98.72%

Operating Margin

-115.53%

Net Income Margin

-154.21%

Return on Equity

192.77%

Return on Capital

N/A

Return on Assets

-63.48%

Earnings Yield

-54.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$497.61M

Shares Outstanding

16.57M

Volume

2

Avg. Volume

276.37K

Financials (TTM)

Gross Profit

$98.33M

Operating Income

-$115.08M

EBITDA

-$106.12M

Operating Cash Flow

-$151.61M

Capital Expenditure

-$532.00K

Free Cash Flow

-$152.14M

Cash & ST Invst.

$202.56M

Total Debt

$13.63M

Sutro Biopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$14.52M

-16.5%

Gross Profit

$13.25M

-23.9%

Gross Margin

91.20%

N/A

Market Cap

$497.61M

N/A

Market Cap/Employee

$1.85M

N/A

Employees

269

N/A

Net Income

-$38.48M

+49.3%

EBITDA

-$27.75M

+39.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$202.56M

-18.6%

Total Debt

$13.63M

-36.3%

Accounts Receivable

$12.48M

-7.9%

Inventory

$0.00

N/A

Long Term Debt

$6.03M

-55.8%

Short Term Debt

$7.60M

-2.1%

Return on Assets

-63.48%

N/A

Return on Invested Capital

-67.23%

N/A

Free Cash Flow

-$42.27M

+38.8%

Operating Cash Flow

-$42.26M

+37.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STTKShattuck Labs, Inc.
$6.01+11.50%
ARTVArtiva Biotherapeutics, Inc.
$9.32-4.90%
IFRXInflaRx N.V.
$1.93+0.00%
CNTBConnect Biopharma Holdings Limited
$2.12+1.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
WENWendy's
$7.86+0.26%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.45+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.30-0.01%
NOKNokia
$13.81+0.01%

Questions About STRO

What is the current price of Sutro Biopharma?

Sutro Biopharma is trading at $30.03 per share.

What is the 52-week range for Sutro Biopharma?

Over the past 52 weeks, Sutro Biopharma has traded between $6.74 and $43.85.

How much debt does Sutro Biopharma have?

As of the most recent reporting period, Sutro Biopharma reported total debt of $242.74M.

How much cash does Sutro Biopharma have on hand?

Sutro Biopharma reported $73.68M in cash and cash equivalents in its most recent financial results.

What is Sutro Biopharma’s dividend yield?

Sutro Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.